To investigate the role of CD45 loss or downregulation in resistance to ALK TKIs, we deleted CD45 by CRISPR/Cas9 system using a sgRNA specific for CD45 in 2 different ALK+ ALCL cell lines (TS and JB6) (Figure 4C). The gene discussed is PTPRC; the disease is anaplastic large cell lymphoma.